BioMarin Announces Updated Strategy for ROCTAVIAN® to Focus on U.S., Germany and Italy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
August 6, 2024 5:02 AM EDTEvercore ISI analyst Cory Kasimov raised the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $115.00 (from $113.00) while maintaining a Outperform rating.
The analyst comments "BMRN printed an encouraging 2Q beat-and-raise w/ solid progress for Voxzogo and long-awaited strategic direction not to mention... More



